Follow the people · Insider
Sireesh Appajosyula
Sireesh Appajosyula files insider transactions with the SEC as a chief operating officer of Hepion Pharmaceuticals (HEPA). We hold 2 disclosed purchases and sales filed since 23 March 2022, 1 of them in the last 90 days.
- Files forHEPA
- Disclosed buys and sells2 in all, 1 in the last 90 days
- Last disclosure12 August 2026
Positions held
3 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 21 April 2026 — 19 August 2026Chief Operating Officer · Hepion Pharmaceuticals (HEPA)4 Form 4 lines · source: SEC Form 4
- Filed 7 November 2023 — 3 November 2025CEO · Tharimmune (THAR)10 Form 4 lines · source: SEC Form 4
- Filed 21 March 2022 — 14 July 2022Director · Hillstream BioPharma (HILS)3 Form 4 lines · source: SEC Form 4
Everything they disclosed
17 entries, newest first — one per disclosure report, one per Form 4 line- was granted 1,345,500 shares of Hepion Pharmaceuticals (a derivative holding)SEC Form 421 August 2026Stock Options · traded 19 August 2026 · filed 21 August 2026
- ▲ bought on the open market 2,000,000 shares of Hepion PharmaceuticalsSEC Form 412 August 2026Common Stock · traded 3 August 2026 · filed 12 August 2026
- ▲ bought on the open market 2,000,000 shares of Hepion Pharmaceuticals (a derivative holding)SEC Form 412 August 2026Warrants · traded 3 August 2026 · filed 12 August 2026
- ▲ bought on the open market 1,250,000 shares of Hepion PharmaceuticalsSEC Form 427 April 2026Common Stock, par value $0.0001 per share · traded 21 April 2026 · filed 27 April 2026
- was granted 20,000 shares of Tharimmune (a derivative holding)SEC Form 45 November 2025Stock Option · traded 3 November 2025 · filed 5 November 2025
- was granted 90,000 shares of Tharimmune (a derivative holding)SEC Form 46 August 2025Stock Option · traded 4 August 2025 · filed 6 August 2025
- ▲ bought on the open market 60,806 shares of TharimmuneSEC Form 423 June 2025Common Stock · traded 20 June 2025 · filed 23 June 2025
- ▲ bought on the open market 690 shares of TharimmuneSEC Form 423 June 2025Common Stock · traded 20 June 2025 · filed 23 June 2025
- was granted 52,875 shares of Tharimmune (a derivative holding)SEC Form 414 January 2025Options (right to buy) · traded 13 January 2025 · filed 14 January 2025
- ▲ bought on the open market 5,000 shares of TharimmuneSEC Form 413 November 2024Common Stock · traded 13 November 2024 · filed 13 November 2024
- ▲ bought on the open market 5,000 shares of TharimmuneSEC Form 49 October 2024Common Stock · traded 8 October 2024 · filed 9 October 2024
- ▲ bought on the open market 5,000 shares of TharimmuneSEC Form 48 October 2024Common Stock · traded 8 October 2024 · filed 8 October 2024
- was granted 38,087 shares of Tharimmune (a derivative holding)SEC Form 412 August 2024Options (right to buy) · traded 9 August 2024 · filed 12 August 2024
- was granted 25,000 shares of Tharimmune (a derivative holding)SEC Form 49 November 2023Options (right to buy) · traded 7 November 2023 · filed 9 November 2023
- gave away 75,757 shares of Hillstream BioPharmaSEC Form 418 July 2022Common Stock · traded 14 July 2022 · filed 18 July 2022
- gave away 7,576 shares of Hillstream BioPharmaSEC Form 418 July 2022Common Stock · traded 14 July 2022 · filed 18 July 2022
- was granted 50,000 shares of Hillstream BioPharma (a derivative holding)SEC Form 423 March 2022Options (right to buy) · traded 21 March 2022 · filed 23 March 2022
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.